AAAP Advanced Accelerator Applications S.A. gains 20% Oct 26, 2017

Advanced Accelerator Applications SA is a radiopharmaceutical company that develops, produces and sells molecular nuclear medicine (MNM), diagnostic and therapeutic products. The Company's lead therapeutic candidate, Lutathera, is being developed for the treatment of midgut neuroendocrine tumors (NETs). The Company has a portfolio of six diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. Its products in clinical development include Lutathera, Somakit and Annexin V-128. The Company's commercial products include Gluscan /Gluscan 500/Barnascan, IASOflu, IASOdopa, IASOcholine, MIBITEC/Adamibi and Leukokit. Lutathera is a solution of a Lu-177-labeled analogue of somatostatin, a hormone that acts as a regulator of the endocrine system. Somakit is the Company's companion PET diagnostic product candidate for Lutathera. Annexin V-128 is a SPECT diagnostic candidate for the assessment of apoptotic and necrotic processes. http://www.priceseries.com/trade/AAAP-Advanced-Accelerator-Applications-SA-stock-gains-20-percent-a-Trade-Record-by-priceSeries-2017092620171026.html